Clinical trials: Movement Abnormalities
Parkinson Disease
Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease
The purpose of this study is to test the safety and efficacy of using of a portable exoskeleton for walking training in persons with Parkinson's disease that have gait mobility problems and/or postural instability.
- Trial name
- NCT04587193
- Testing
- Robotic-assist gait training device
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Tourette Syndrome
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
- Trial name
- NCT02879578
- Testing
- Valbenazine
- Where
- 13 sites in United States
- Volunteers
- 155 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease, Impaired Cognition
Cognitive Training in Parkinson Study
This study evaluates the efficacy of an eight-week online cognitive training program on objective and subjective cognitive functions in Parkinson's disease.
- Conditions
- Parkinson Disease, Impaired Cognition, Alteration in Cognition
- Trial name
- cogtips (NCT02920632)
- Testing
- Online cognitive training 1, Online cognitive training 2
- Where
- Netherlands
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Parkinson Disease
SCH: Context-aware Freezing of Gait Mitigation in Real-world Setting
People with Parkinson's disease (PD) may experience a walking problem called freezing of gait (FoG) that can interfere with the person's ability to conduct daily activities.
- Trial name
- NCT04746846
- Testing
- UG motion sensor with PDVibe3
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Commonwealth University
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Huntington Disease
Effect of Tetrabenazine on Stroop Interference in HD
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing.
- Trial name
- NCT01834911
- Testing
- Tetrabenazine withdrawal
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Orthostatic Hypotension, Idiopathic Parkinson Disease
Lundbeck TOMs Orthostatic Hypotension
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD).
- Trial name
- NCT04510922
- Testing
- Droxidopa 100 MG [Northera]
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alberto Espay, MD, MSc
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline
Sialorrhoea
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
- Trial name
- NCT01370811
- Testing
- oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Orient Pharma Co., Ltd.
Parkinson Disease
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.
- Trial name
- NCT02305316
- Testing
- BIA 9-1067 non-micronized, BIA 9-1067 micronized
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or…
- Trial name
- NCT00650104
- Testing
- Ropinirole XL (formerly CR)
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- GlaxoSmithKline
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Huntington Disease
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD).
- Trial name
- NCT03515213
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Parkinson Disease
Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease
The researchers have developed a multifunctional rehabilitation device that will be tested in this feasibility trial across three sub-studies: (i) dual session in-lab; (ii) multi-session in-lab and (iii) in the participant's…
- Trial name
- NCT05586490
- Testing
- Multifunctional RehabilitationDevice (MRD), existing standard rehabilitation device
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Michigan
Parkinson's Disease
Repurposing Lithium for Parkinson's Disease
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
- Trial name
- NCT06099886
- Testing
- Lithium aspartate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- State University of New York at Buffalo
Essential Tremor
A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor
The purpose of this study is to determine the effects of Low Frequency Repetitive Transcranial Magnetic Stimulation (LF r-TMS) of the pre-Supplementary Motor Area (pre-SMA) on tremor as measured by the tremor rating scale (TRS)…
- Trial name
- NCT02763865
- Testing
- MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Dyskinesia, Levodopa Induced Dyskinesia (LID)
Open-Label Safety Study of ADS-5102 in PD Patients With LID
This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- NCT02202551
- Testing
- ADS-5102
- Where
- 87 sites in United States, Austria and 4 more
- Volunteers
- 223 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals